Nexentis Technologies Inc. is a Nevada incorporated company that focuses on sustainable operations through two core business areas. The first area is oncology biotechnology conducted by its wholly owned subsidiary MitoCareX Bio Ltd which develops drug candidates that target mitochondrial carrier proteins for cancer and inflammatory metabolic diseases. The second area is solar energy project development carried out by its subsidiary Solterra Renewable Energy Ltd which…
Nexentis Technologies Inc. is a Nevada incorporated company that focuses on sustainable operations through two core business areas. The first area is oncology biotechnology conducted by its wholly owned subsidiary MitoCareX Bio Ltd which develops drug candidates that target mitochondrial carrier proteins for cancer and inflammatory metabolic diseases. The second area is solar energy project development carried out by its subsidiary Solterra Renewable Energy Ltd which identifies develops and sells renewable energy projects in Europe primarily in Italy Poland and Germany.
Nexentis generates revenue from several sources. MitoCareX plans to earn income through licensing of its MITOLINE platform milestone payments and royalties on future approved therapeutics. Solterra derives revenue from the sale of solar energy projects to third parties at various stages of development. Additionally the company provides non exclusive advisory support and collaboration services to Voice Assist under a services agreement receiving deferred cash royalty consideration and a share of any Ecolab gross proceeds.
The company operates through the following segments.
- MitoCareX Bio Ltd.: a drug discovery company focused on developing therapeutics targeting the mitochondrial carrier family for cancer and inflammatory metabolic diseases using its proprietary MITOLINE algorithm and computational platform to identify and advance small molecule compounds.
- Solterra Renewable Energy Ltd.: a solar energy project developer that engages in the identification development and sale of renewable energy projects in Europe primarily in Italy Poland and Germany with a business model centered on selling projects at various stages of development to third parties.
Nexentis holds a niche position in the biotechnology sector where MitoCareX differentiates itself through its MITOLINE algorithm that enables reliable three dimensional modeling of mitochondrial carrier proteins a capability not widely available among competitors. In the solar energy space Solterra operates as a project developer in markets where large integrated utilities and specialized local firms compete for opportunities but the company focuses on early stage project identification and sale to third parties allowing it to leverage technical expertise without bearing long term construction and operation risks.
MitoCareX sells its platform access and potential drug candidates to pharmaceutical and biotechnology firms seeking novel targets for cancer and metabolic diseases. Solterra sells its solar projects to utilities independent power producers and other renewable energy investors. The company also provides advisory services to Voice Assist a publicly traded Nevada corporation.